<i>EGFR</i> V834L and L858R Comutation Is Associated With Response to Osimertinib in Non–Small-Cell Lung Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

EGFR V834L and L858R Comutation Is Associated With Response to Osimertinib in Non–Small-Cell Lung Cancer

Published:2024-07 Issue:8 Volume: Page:
ISSN:2473-4284
Container-title:JCO Precision Oncology
language:en
Short-container-title:JCO Precis Oncol

Author:

Giustini Nicholas P.¹^ORCID,Pritchard Colin C.²^ORCID,Kamat Nikhil V.¹^ORCID,Menon Manoj P.¹^ORCID

Affiliation:

1. Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA

2. Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA

Abstract

Up-front osimertinib leads to clinical benefit in EGFR V834L and L858R comutated NSCLC.

Publisher

American Society of Clinical Oncology (ASCO)

Link

https://ascopubs.org/doi/pdfdirect/10.1200/PO.23.00215

Reference10 articles.

1. A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer

2. Clinical Impact of Rare and Compound Mutations of Epidermal Growth Factor Receptor in Patients With Non–Small-Cell Lung Cancer

3. Effectiveness of Tyrosine Kinase Inhibitors on “Uncommon” Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non–Small Cell Lung Cancer

4. The in cis compound EGFR mutations in Chinese advanced non-small cell lung cancer patients

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP